Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny trial tests new lead for implanted defibrillator

NCT ID NCT06592001

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new type of lead (a wire) for an implantable cardioverter-defibrillator (ICD) in 19 people who need one. The lead is placed under the breastbone to deliver a shock if the heart beats dangerously fast. The goal is to see if it is safe and works well enough to plan a larger study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AtaCor EV-ICD Atala™ lead (implanted device)
What this could lead to
If successful, this could lead to a safer, more effective way to deliver life-saving shocks from an implantable defibrillator to prevent sudden cardiac death.
What could go wrong
This is a very small, early feasibility study with only 19 people and no control group. The device may not work as expected or could cause complications like infection or lead failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Feb 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At least 18 years old 2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines Exclusion Criteria: 1. Participation in any concurrent clinical study without prior written approval from the Sponsor 2. Inability or unwillingness to provide informed consent to participate in the Study 3. Any known conditions which may complicate the AtaCor EV-ICD Lead System implant procedure or prevent the subject from completing protocol testing through the 3-month follow-up visit 4. Circumstances that may prevent data collection or completion of specified follow-up visits 5. Allergies to any device materials listed in the Instructions for Use (IFU) 6. Subjects on anticoagulation therapy that cannot be temporarily discontinued for the procedure 7. Known history of lung disease with FEV1 \< 1.0 Liter Device Related: 8. Presence or planned use of medical devices that introduce current into the body (e.g., pacemaker, LVAD, neurostimulator, etc.) 9. Implanted with or planned implantation of any device which delivers current in the body, that may interfere with therapy delivery, including, but not limited to a pacemaker, or neurostimulator 10. Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads 11. Any known need for future MRI Anatomy Related: 12. BMI ≥ 35 kg/m2 13. Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum 14. Prior sternotomy of any type, including but not limited to median, mini or clamshell 15. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium 16. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) and associated with displacement of the heart or lungs or impeded mediastinal access. 17. History of thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV-ICD Lead System implant procedure 18. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax 19. Surgically corrected congenital heart disease (not including catheter-based procedures) Cardiac Related: 20. Subjects who require permanent bradycardia pacing or cardiac resynchronization therapy 21. NYHA IV functional class in past 90 days 22. Inotropic therapy in past 180 days 23. Known history of pericardial disease, pericarditis or mediastinitis 24. Patients with a medical condition that precludes them from undergoing defibrillation testing: * Severe aortic stenosis * Current Intracardiac LA or LV thrombus * Severe proximal three-vessel or left main coronary artery disease without revascularization * Hemodynamic instability * Unstable angina * Recent stroke or transient ischemic attack (within the last 6 months) * Known inadequate external defibrillation * LVEF \< 20% * LVEDD \>70 mm

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventricular arrythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Christchurch Hospital

    Christchurch, New Zealand

  • Sanatorio Italiano

    Asunción, Paraguay

  • University Hospital Center Split

    Split, 21000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.